G-CSF: Boosting endogenous production - A new strategy?

Sonja von Aulock, Isabel Diterich, Lars Hareng, Thomas Hartung

Research output: Contribution to journalArticle

Abstract

Granulocyte colony-stimulating factor (G-CSF) has been in clinical use for over a decade. Its main applications are in adjunctive medication to chemotherapy and in mobilizing stem cells for bone marrow transplantation. However, it has additional effects in that it primes neutrophilic granulocytes for improved host defense, and reduces the release of pro-inflammatoiy cytokines. These effects have prompted trials for numerous other indications. New research into the production and regulation of G-CSF in health and disease may now enable tailored strategies to induce or boost G-CSF formation. Similarly, new forms of application may increase its effectiveness.

Original languageEnglish (US)
Pages (from-to)1148-1152
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Volume5
Issue number11
StatePublished - Nov 1 2004
Externally publishedYes

Keywords

  • Clinical applications
  • Endogenous production
  • Granulocyte colony-stimulating factor
  • Lyme borreliosis
  • Sepsis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'G-CSF: Boosting endogenous production - A new strategy?'. Together they form a unique fingerprint.

  • Cite this